Raymond J. Kelleher is managing director at Cormorant Asset Management, where he invests in public and private companies across all therapeutic areas. He represents Cormorant on the boards of Axonis Therapeutics, BiVACOR, Bridgebio Oncology Therapeutics, Expansion Therapeutics, Garuda Therapeutics, GC Therapeutics, Kamau Therapeutics, Neurona Therapeutics, Rapport Therapeutics and Triveni Therapeutics as director, and Chroma Therapeutics, Interius BioTherapeutics and Umoja Biopharma as observer.

Ray is also an attending neurologist at Massachusetts General Hospital, where he maintains a clinical practice focused on memory disorders and dementia. His research has made important contributions to understanding the molecular and cellular basis of neurological disease. His work has been published in Cell, Nature, Neuron and elsewhere, and his research has received numerous national honors, including the Pew Scholars Award in the Biomedical Sciences, the John Merck Scholars Award and the NIH Independent Scientist Award.

Ray completed B.S. degrees in biology and literature at MIT, an A.M. in French at Harvard University, and an M.D. and a Ph.D. in cell biology through the Medical Scientist Training Program at Stanford University. His Ph.D. research with Nobel Laureate Roger Kornberg at Stanford resulted in discovery of the Mediator complex responsible for transcriptional activation, and his postdoctoral research with Nobel Laureate Susumu Tonegawa at MIT identified a key role for translational control in memory formation. He completed his clinical training at MGH and Harvard Medical School.